SEQUENT

Sequent Scientific Share Price

₹178.40 +1.29 (0.73%)

22 Jan, 2025 12:15

SIP TrendupStart SIP in SEQUENT

Start SIP

Performance

  • Low
  • ₹177
  • High
  • ₹184
  • 52 Week Low
  • ₹92
  • 52 Week High
  • ₹241
  • Open Price₹178
  • Previous Close₹177
  • Volume420,857

Investment Returns

  • Over 1 Month + 0.68%
  • Over 3 Month -5.65%
  • Over 6 Month + 26.6%
  • Over 1 Year + 28.9%
SIP Lightning

Smart Investing Starts Here Start SIP with Sequent Scientific for Steady Growth!

Invest Now

Sequent Scientific Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 220.4
  • PEG Ratio
  • 1.9
  • Market Cap Cr
  • 4,454
  • P/B Ratio
  • 6.6
  • Average True Range
  • 9.25
  • EPS
  • 0.78
  • Dividend Yield
  • 0
  • MACD Signal
  • -2.6
  • RSI
  • 45.41
  • MFI
  • 43.93

Sequent Scientific Financials

Sequent Scientific Technicals

EMA & SMA

Current Price
₹178.40
+ 1.29 (0.73%)
pointer
  • stock-down_img
  • Bearish Moving Average 11
  • stock-up_img
  • Bullish Moving Average 5
  • 20 Day
  • ₹181.69
  • 50 Day
  • ₹185.18
  • 100 Day
  • ₹180.57
  • 200 Day
  • ₹165.18

Resistance and Support

181.05 Pivot Speed
  • R3 201.66
  • R2 196.10
  • R1 186.61
  • S1 171.56
  • S2 166.00
  • S3 156.51

What's your outlook on Sequent Scientific?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sequent Scientific Ltd. is a leading animal health company in India, specializing in the manufacturing of veterinary pharmaceuticals, including APIs and formulations. It serves global markets with a strong focus on quality, compliance, and innovation.

Sequent Scientific has an operating revenue of Rs. 1,449.42 Cr. on a trailing 12-month basis. An annual revenue de-growth of -3% needs improvement, Pre-tax margin of -4% needs improvement, ROE of -5% is poor and needs improvement. The company has a reasonable debt to equity of 22%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 14% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 26% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sequent Scientific Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-14 Quarterly Results
2024-05-15 Audited Results & Final Dividend
2024-02-13 Quarterly Results
2023-11-06 Quarterly Results
Date Purpose Remarks
2021-09-10 FINAL Rs.0.50 per share(25%)Final Dividend
View More

Sequent Scientific F&O

Sequent Scientific Shareholding Pattern

52.76%
7.41%
6.45%
24%
9.38%

About Sequent Scientific

  • NSE Symbol
  • SEQUENT
  • BSE Symbol
  • 512529
  • Managing Director & CEO
  • Mr. Rajaram Narayanan
  • ISIN
  • INE807F01027

Similar Stocks to Sequent Scientific

Sequent Scientific FAQs

Sequent Scientific share price is ₹178 As on 22 January, 2025 | 12:01

The Market Cap of Sequent Scientific is ₹4453.6 Cr As on 22 January, 2025 | 12:01

The P/E ratio of Sequent Scientific is 220.4 As on 22 January, 2025 | 12:01

The PB ratio of Sequent Scientific is 6.6 As on 22 January, 2025 | 12:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23